Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,627
Total Claims
$1.3M
Drug Cost
1,059
Beneficiaries
$1,221
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-71%
Opioid rate vs peers
0.7% vs 2.6% avg
+14%
Cost per patient vs peers
$1,221 vs $1,068 avg
+45%
Brand preference vs peers
13.1% vs 9.0% avg
Opioid Prescribing
0.7%
Opioid Rate
64
Opioid Claims
$624
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,114 claims · $1.1M
Generic: 7,406 claims · $171K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phos/Metformin Hcl | 66 | $74K |
| Apixaban | 76 | $65K |
| Sitagliptin Phosphate | 41 | $61K |
| Dulaglutide | 34 | $59K |
| Fluticasone/Umeclidin/Vilanter | 38 | $46K |
| Semaglutide | 24 | $33K |
| Empagliflozin | 28 | $33K |
| Budesonide/Formoterol Fumarate | 37 | $32K |
| Rivaroxaban | 27 | $26K |
| Sacubitril/Valsartan | 20 | $26K |
| Insulin Glargine,hum.Rec.Anlog | 40 | $24K |
| Tirzepatide | 18 | $23K |
| Insulin Glargine,hum.Rec.Anlog | 14 | $19K |
| Insulin Glargine/Lixisenatide | 13 | $19K |
| Ticagrelor | 13 | $13K |
Prescribing Profile
Patient Profile
69
Avg Age
61%
Female
1.51
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data